id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-301281-yur5hs2h	Zelek, Wioleta M.	Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19	2020-11-01		.txt	text/plain	1671	87	44	We here report the contribution of complement activation and impact of complement blockade in severe COVID-19, defined as marked respiratory impairment requiring intensive care and ventilation support. Five patients were selected, based on high levels of TCC (above the mean 1 2 SD for controls; 7.14 mg/L) and either treatment failure (patients 1-3) or failure to improve (patients 4 and 5) where death was not considered imminent (clinical judgement), for inclusion in a compassionate use study of complement blockade using LFG316 (tesidolumab; Novartis Managed Access Program), a C5-blocking monoclonal antibody (mAb) that prevents generation of the proinflammatory effectors C5a and membrane attack complex (6) . We describe a preliminary evaluation of the potential benefit of C5 blockade in severe COVID-19; we show that the C5-blocking mAb LFG316 could be administered in critically ill mechanically ventilated patients with COVID-19; a single dose of LFG316 blocked C5 activity and complement activation for at least 4 days in all treated patients.	./cache/cord-301281-yur5hs2h.txt	./txt/cord-301281-yur5hs2h.txt